Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: A prospective study

Cancer

Volumn 91, Issue 12, 2001, Pages 2386-2393

  Song, Byung Cheol ^a   Chung, Young Hwa ^a   Kim, Jeong A ^b   Lee, Han Chu ^a   Yoon, Hyun Ki ^c   Sung, Kyu Bo ^a   Hyunyang, Soo ^a   Yoo, Kwon ^a   Lee, Yung Sang ^a   Suh, Dong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Korean Veterans Hospital   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

Author keywords

Hepatocellular carcinoma; Insulin like growth factor 2 (IGF 2); Metastasis; Transcatheter arterial chemoembolization (TACE)

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; GELFOAM; IODINATED POPPYSEED OIL; SOMATOMEDIN B;

ADULT; ARTICLE; ARTIFICIAL EMBOLISM; CANCER SIZE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES;

EID: 0035876139     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010615)91:12<2386::AID-CNCR1272>3.0.CO;2-4     Document Type: Article

References (40)

1. A 5-year experience of lipiodolization: Selective regional chemotherapy for 200 patients with hepatocellular carcinoma
2. Prognostic factors in the treatment of hepatocellular carcinoma with transcatheter arterial embolization and arterial infusion
3. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model
4. Response to transcatheter oily chemoembolization in hepatocellular carcinoma 3 cm or less: A study in 50 patients who underwent surgery
5. Unresectable hepatocellular carcinoma: Analysis of prognostic factors in transcatheter management
6. Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials
7. Pulmonary metastasis of hepatocellular carcinoma associated with transarterial chemoembolization
8. Insulin-like growth factors and their binding proteins: Biologic actions
9. Insulin-like growth factors
10. Insulin-like growth factor and cancer
11. The insulin-like growth factor-I receptor: A key to tumor growth?
12. Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: Implications of IGF-I receptor gene activation by hepatitis B virus X gene product
13. Reactivation of insulin-like growth factor II during hepatocarcinogenesis in transgenic mice suggests a role in malignant growth
14. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice
15. Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma
16. Insulin-like growth factor II (IGF-II) secreted from HepG2 human hepatocellular carcinoma cells shows angiogenic activity
17. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis
18. Expression of insulin-like growth factor II (IGF-II) in human primary liver cancer: mRNA and protein analysis
19. Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma: Its relationship with hepatitis B virus antigen expression
20. Differential expression of transforming growth factor α and insulin-like growth factor II in chronic active hepatitis B, cirrhosis and hepatocellular carcinoma
21. Serum alpha-fetoprotein in hepatocellular carcinoma
22. Recurrence of hepatocellular carcinoma following initial remission by transarterial chemoembolization
23. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil
24. Pathology of small hepatocellular carcinoma. A proposal for a new gross classification
25. Reporting results of cancer treatment
26. The biology of human cancer metastasis
27. Clinical application of research on angiogenesis
28. Histologic assessment of resected hepatocellular carcinoma after transcatheter hepatic arterial embolization
29. Limitation of transcatheter arterial chemoembolization using iodized oil for small hepatocellular carcinoma. A study in resected cases
30. Effects of preoperative transcatheter hepatic arterial chemoembolization for hepatocellular carcinoma. The relationship between postoperative course and tumor necrosis
31. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: A reappraisal
32. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-α for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis
33. Depressed natural killer cell activity in patients with hepatocellular carcinoma. In vitro effects of interferon and levamisole
34. Insulin receptor substrate 1 overexpression in human hepatocellular carcinoma cells prevents transforming growth factor betal-induced apoptosis
35. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes
36. Substrate adhesiveness and experimental metastatic potential of rat ascites hepatoma AH7974-derived variant sublines
37. Spontaneous and iatrogenic spreading of liver-derived cells into peripheral blood of patients with primary liver cancer
38. Presence of alpha-fetoprotein mRNA in blood correlates with outcome in patients with hepatocellular carcinoma
39. Radioimmunoassay of serum IGF-I and IGF-II in patients with chronic liver diseases and hepatocellular carcinoma with or without hypoglycemia
40. Serum insulin-like growth factor II in chronic liver disease